Interestingly, icatibant, which is used in the on-demand treatment of acute HAE-C1-INH attacks due to its blockade of the bradykinin B2 (BDKRB2) receptor, has been also demonstrated to trigger MRGPRX2 (9, 104). This evidence concerns the gene MRGPRX2 and hereditary angioedema.